Active substance
Meropenem
- SFDA 19
- US FDA 16
- Health Canada 15
- US price lines 1
- WHO EML 3
- Safety 8
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ARCHIFAR 1000 mg powder for solution for injection or infusion | 1000 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 395.90 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| ARCHIFAR 500 mg powder for solution for injection or infusion | 500 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 232.85 | Generic · Prescription | MEDOCHEMIE LTD PHARMACEUTICAL INDUSTRY | Valid |
| MERONEM 1GM VIAL I-V | 1 g | powder for solution for injection · Intravenous use | 10 Vial | SAR 890.60 | NCE · Prescription | Pfizer Limited | Valid |
| MERONEM 500MG VIAL I-V | 500 mg | powder for solution for injection · Intravenous use | 10 Vial | SAR 473.85 | NCE · Prescription | Pfizer Limited | Valid |
| MEROPENEM KABI. | 1000 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 356.40 | Generic · Prescription | Fresenius Kabi Deutschland GmbH | Valid |
| MEROPENEM KABI. | 500 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 211.95 | Generic · Prescription | Fresenius Kabi Deutschland GmbH | Valid |
| MEROZA 1 g powder for Solution for Injection or Infusion | 1 g | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 356.40 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| MEROZA 500 mg powder for Solution for Injection or Infusion | 500 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 211.95 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| MIRAN 0.5 g powder for injection | 500 mg | Powder for injection · Intravenous use | 1 Vial | SAR 23.55 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| MIRAN 1 g powder for injection | 1 g | Powder for injection · Intravenous use | 1 Vial | SAR 39.60 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Meropa | 1000 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 356.40 | Generic · Prescription | Hikma FARMACEUTICA Portugal SA | Valid |
| Meropa | 500 mg | Powder for solution for injection/infusion · Intravenous use | 10 Vial | SAR 211.95 | Generic · Prescription | Hikma FARMACEUTICA Portugal SA | Valid |
| RONEM 1GM | 1 g | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 662.45 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| RONEM 500MG | 500 mg | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 344.85 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| Ultranem | 1000 mg | Powder for solution for infusion · Intravenous use | 10 Vial | SAR 356.40 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| Ultranem | 500 mg | Powder for solution for infusion · Intravenous use | 10 Vial | SAR 211.95 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| Ultranem | 2000 mg | Powder for solution for infusion · Intravenous use | 6 Vial | SAR 840.00 | Generic · Prescription | Advanced Pharmaceutical Industries | Valid |
| MEPRA 1 g powder for solution for injection or infusion | 1 g | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 439.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| MEPRA 500 mg powder for solution for injection or infusion | 500 mg | Powder for solution for injection/infusion · Parenteral use | 10 Vial | SAR 258.70 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE BACTERIAL PROSTATITIS; ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); ACUTE PANCREATITIS; ACUTE PYELONEPHRITIS; BACTERIAL MENINGITIS; BACTERIAL SKIN INFECTIONS - CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; COMMUNITY ACQUIRED PNEUMONEA; ENDOCARDITIS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; INTRA-ABDOMINAL INFECTIONS; OSTEOMYELITIS; PERITONITIS; Pyogenic Arthritis; Septic Shock; TRAVEL RELATED INFECTIONS-TREATMENT; TUBERCULOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | ACS DOBFAR | Prescription | 26 Oct 2011 |
| MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | 500MG/VIAL; 1GM/VIAL | powder · intravenous | B BRAUN MEDICAL | Prescription | 30 Apr 2015 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | AMNEAL PHARMS | Prescription | 12 Apr 2016 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | SAVIOR LIFETEC CORP | Prescription | 19 Apr 2016 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | GLAND | Prescription | 8 Jun 2016 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | ACS DOBFAR SPA | Prescription | 9 Jun 2016 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | EUGIA PHARMA | Prescription | 27 Mar 2017 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | HQ SPCLT PHARMA | Prescription | 16 Aug 2019 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | BROOKS STERISCIENCE | Prescription | 18 Aug 2022 |
| MEROPENEM | 2GM/VIAL | powder · intravenous | HQ SPCLT PHARMA | Prescription | 26 Jul 2023 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | QILU | Prescription | 22 Jul 2024 |
| MEROPENEM | 2GM/VIAL | powder · intravenous | BROOKS STERISCIENCE | Prescription | 23 Jun 2025 |
| MERREM IV | 1GM/VIAL; 500MG/VIAL | injectable · injection | PFIZER | Discontinued | 21 Jun 1996 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | HOSPIRA INC | Discontinued | 22 Jun 2010 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | SANDOZ | Discontinued | 29 Mar 2011 |
| MEROPENEM | 500MG/VIAL; 1GM/VIAL | injectable · injection | DAEWOONG PHARM CO | Discontinued | 18 Dec 2015 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MEROPENEM FOR INJECTION | 02378787 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| MEROPENEM FOR INJECTION | 02378795 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SANDOZ CANADA INCORPORATED |
| MEROPENEM FOR INJECTION | 02462885 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| MEROPENEM FOR INJECTION | 02462893 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | AURO PHARMA INC |
| MEROPENEM FOR INJECTION | 02493330 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| MEROPENEM FOR INJECTION | 02493349 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | STERIMAX INC |
| MEROPENEM FOR INJECTION | 02528819 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| MEROPENEM FOR INJECTION | 02528827 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| MEROPENEM FOR INJECTION | 02536374 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | JAMP PHARMA CORPORATION |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 02544334 | 500 MG / CONTAINER | POWDER FOR SOLUTION · INTRAVENOUS | B. BRAUN MEDICAL INC |
| MEROPENEM FOR INJECTION USP AND SODIUM CHLORIDE INJECTION USP | 02544342 | 1 G / CONTAINER | POWDER FOR SOLUTION · INTRAVENOUS | B. BRAUN MEDICAL INC |
| MEROPENEM FOR INJECTION, USP | 02415216 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| MEROPENEM FOR INJECTION, USP | 02415224 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| TARO-MEROPENEM | 02421518 | 500 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SUN PHARMA CANADA INC |
| TARO-MEROPENEM | 02421526 | 1 G / VIAL | POWDER FOR SOLUTION · INTRAVENOUS | SUN PHARMA CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MEROPENEM IV 1 GM VIAL | $4.68755 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.2. Watch group antibiotics · complementary
Second choice: Neonatal meningitis; Second choice: Peritoneal abscess (severe); Second choice: Neutropaenia (high-risk); Second choice: Peritonitis (severe)
Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection (EMLc); 1 g in vial (as trihydrate) powder for injection (EMLc) | Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection - 5.1.6.1. Medicines for bacterial central nervous system infections · complementary
Second choice: Neonatal meningitis
Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection (EMLc); 1 g in vial (as trihydrate) powder for injection (EMLc) - 6.2.5. Antituberculosis medicines · core
Multi-drug resistant Mycobacterium tuberculosis
Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
Safety signals and safety-related labeling changes
- US FDA 20 Feb 2026 VABOMERE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 May 2025 MERREM IV — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 3 Dec 2024 MEROPENEM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions - US FDA 3 Dec 2024 MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations - US FDA 3 Dec 2024 MERREM — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 6 Jul 2017 PRAC signal: Incompatibility leading to possible precipitation when co-administered intravenously
Action for MAH: update of the product information: Yes - EMA PRAC 9 Mar 2017 PRAC signal: Incompatibility leading to possible precipitation when co-administered intravenously
Action for MAH: update of the product information: No - EMA PRAC 1 Dec 2016 PRAC signal: Incompatibility leading to possible precipitation when co-administered intravenously
Action for MAH: update of the product information: No
Combinations containing Meropenem
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.